Candel Therapeutics’ CAN-2409 Trial Results Accepted at ASCO

An announcement from Candel Therapeutics ( (CADL) ) is now available.

On April 23, 2025, Candel Therapeutics announced that an abstract featuring positive results from their phase 3 clinical trial of CAN-2409 in localized prostate cancer was accepted for oral presentation at the 2025 ASCO Annual Meeting. The trial demonstrated significant improvement in disease-free survival when CAN-2409 was added to standard-of-care radiation therapy, highlighting its potential impact on cancer treatment and Candel’s positioning in the biopharmaceutical industry.

Spark’s Take on CADL Stock

According to Spark, TipRanks’ AI Analyst, CADL is a Underperform.

Candel Therapeutics faces substantial financial hurdles with no revenue and ongoing cash burn. While recent positive trial results provide some hope for future growth and development, the technical analysis and valuation remain negative. The stock is highly speculative, with potential upsides hinging on the success of pipeline developments and financial stabilization.

To see Spark’s full report on CADL stock, click here.

More about Candel Therapeutics

Candel Therapeutics is a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer. Their lead product candidate, CAN-2409, is an off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase gene to tumors, inducing a systemic immune response. Candel’s development program includes trials in various cancers, with CAN-2409 showing potential in treating a broad range of solid tumors.

YTD Price Performance: -47.33%

Average Trading Volume: 1,091,598

Technical Sentiment Signal: Buy

Current Market Cap: $223.7M

See more insights into CADL stock on TipRanks’ Stock Analysis page.